OXFORD, England--(BUSINESS WIRE)--Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced today to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health.
“On our path to develop next-generation RNA medicines with the potential to improve the lives of patients in need of a liver transplant, we are grateful to have access to discarded donor livers, allowing us to develop therapeutics that are safe and effective when we enter the clinical evaluation stage,” said Jack O’Meara, CEO at Ochre Bio. “As we are progressing our preclinical evaluation, we are proud to support the great work of the British Liver Trust. We highly appreciate their effort in supporting patients, caregivers, and healthcare professionals on all aspects of liver health including prevention and early detection, and we look forward to a close partnership as we execute on our unified goal.”
The British Liver Trust is the UK's leading liver health charity, recognised by Her Majesty's Revenue and Customs (HMRC) and the Charity Commissions in England, Wales and Scotland, is working to improve liver health and supporting patients affected by liver disease or cancer. Reaching millions of people each year, the British Liver Trust raises awareness for the risk factors of liver disease, provides advice to help people improving their liver health and submits the most updated information to patients.
“In the UK, one out of six patients dies while waiting for a liver transplant. Ochre Bio’s research has the potential to improve these numbers and with that the chances of successful treatment for liver disease patients. We are really excited that Ochre Bio is supporting the aims of the British Liver Trust and we delighted to have this partnership with important shared goals,” added Pamela Healy OBE, Chief Executive of the British Liver Trust
About Ochre Bio
Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases, a top ten global killer. We uncover new biological pathways by using advances in 'deep phenotyping', and then study our medicines in human livers kept alive on machines. In doing so, Ochre Bio ensures that the medicines we bring to the clinic are highly likely to successfully improve patient lives. Situated within the heart of Oxford’s biotech innovation hub, Ochre is built on over 15 years experience in liver genomics and bringing advanced therapies to market. To learn more, please visit www.ochre-bio.com.